Tuesday, October 31, 2006

HCP/Market Conditioning Website (Prostate Cancer)

ABOUT SERA
 
Abbott is researching selective endothelin-A receptor antagonists (SERAs) to determine their potential to change the natural progression of cancer by blocking endothelin-1 (ET-1) from binding to the endothelin-A (ETA) receptor.
buzz this

0 comments: